US biosimilar developers plan around numbers a statute hands them. The statute gives twelve years of reference-product exclusivity from first licensure under 42 U.S.C. § 262(k)(7)(A), a bar on filing before year four under § 262(k)(7)(B), and an interchangeability designation under § 262(k)(4) that decides whether a pharmacist may substitute at all.142 U.S.C. § 262(k)(7)(A) and (B), § 262(k)(4), § 262(k)(6) and § 262(l) (BPCIA). Europe has long been the earlier market for biosimilars, and the European half of a global launch calendar has been the half a developer could compute rather than negotiate. The count was eight years of data protection, two of market protection, one more if the originator added an indication in time. The EU Pharma Package keeps the arithmetic simple and makes the inputs invisible. The reference product's clock is still set by statute, but its length is decided by facts an entrant cannot observe, in procedures it is not party to, and, for the first time, Member State by Member State.
1. The Same Clock, Read From the Outside
The originator's side of the new protection architecture has been examined on this site, in the map of the sponsor decisions the Package closes and in the article on the 90-day filing rule, so one paragraph of background suffices. Under Art. 80(1) of the revised Directive, the data supporting a marketing authorization may not be relied on by another applicant for eight years from the initial authorization. Under Art. 80(2) of the revised Directive, the subsequent product may not be placed on the market for one further year, the regulatory market protection period. Art. 81(2) of the revised Directive then offers four mutually exclusive twelve-month prolongations of that market protection, for an unmet medical need demonstrated at the initial application, or, for products containing a new active substance, for an evidence-based comparator paired with a Union-first or 90-day filing, for that comparator paired with multi-Member-State efficacy trials, or for the multi-Member-State and filing conditions together where a comparator was justifiably impossible. Art. 81(2a) of the revised Directive adds one further year, once, where a new indication of significant clinical benefit is authorized during the data protection period. Art. 81(2b) of the revised Directive caps cumulative market protection at two years beyond data-protection expiry, the year under Art. 81(2a) of the revised Directive alone stacking above the cap. Both clocks run from the initial authorization of the global marketing authorization under Art. 5(2) of the revised Directive, so a line extension does not restart them.2Council compromise text for the revised Directive, Council doc ST-6367/26 (6 March 2026), Art. 80(1) and (2), Art. 81(2), (2a) and (2b), Art. 82, Art. 5(2). Against the outgoing regime of Art. 10(1) of Directive 2001/83/EC, eight years of data protection, ten before market entry and one more for a significant-benefit indication, the floor has dropped by a year, the eleven-year ceiling is reached through two conditional years rather than one, and a voucher can lift it further still.3Directive 2001/83/EC, Art. 10(1) and (4); Directive ST-6367/26 (n 2), Art. 218(5), Art. 219(1), Art. 220; Regulation ST-6366/26, Art. 180(4); Regulation (EC) No 726/2004, Art. 14(11).
Read from the entrant's side, every one of those conditional years is a fact the entrant learns late. The unmet-medical-need year is claimed at the originator's initial application but gated on release and continuous supply under Art. 82(1) of the revised Directive and delivered through a variation the holder applies for under Art. 82(2) of the revised Directive. The new-indication year under Art. 81(2a) of the revised Directive depends on an authorization the holder may obtain at any point in the eight-year data protection period, so a biosimilar program planned in year three against a nine-year horizon can find, in year seven, that the horizon is ten. The compromise text's answer to that opacity is a register. Under Art. 80(5a) of the revised Directive national competent authorities are to publish lists of the products they have nationally authorized that are under regulatory protection, indicating the applicable prolongation, and the European Medicines Agency (the Agency, in the Package's own usage) is to compile and publish the hyperlinks. The provision is framed around national marketing authorizations. For a centrally authorized biologic, which is the reference product for most biosimilars, the Package points instead to the Commission's Union Register of medicinal products. Recital 31a of the Regulation expects the Register to show the applicable prolongations, while the operative text, Art. 16(1) of the Regulation, obliges the Commission only to add the product to the Register and give it a number. Art. 80(5) of the Directive adds that the data protection runs even in Member States where the reference product is not, or is no longer, authorized.4Directive ST-6367/26 (n 2), Art. 80(5) and (5a), Art. 81(2a), Art. 82(1) and (2); Regulation ST-6366/26 (n 3), Art. 16(1), Recital 31a.
A second input sits in the companion Regulation. A transferable exclusivity voucher earned by a priority antimicrobial adds twelve months to the data protection of one centrally authorized product, the antimicrobial itself or another centrally authorized product of the same or a different holder. Where it lands on a different product it may be used only in the fifth or sixth year of that product's data protection, and only where the product's annual gross Union sales did not exceed EUR 490 million in any of its first four years.5Regulation ST-6366/26 (n 3), Art. 40(2), Art. 41(1) to (4), Art. 42(1), Recital 82. For the entrant that is a year of data protection which appears, if it appears, two to three years before a planned filing, on exactly the mid-sized biologics a biosimilar program is most likely to target, because the blockbuster cap steers the voucher away from the largest products. The transfer and its value are published by the Agency under Art. 41(4) of the Regulation, and Recital 82 expects the identity of the holder of an unused voucher to be publicly known at all times. The register tells the entrant that a voucher exists and who holds it, not where it will be used. The voucher's economics are a subject of their own. Its effect on a biosimilar calendar is simpler, a year that the entrant cannot price in until an originator has bought it.
The third input is the one most likely to be misread, because it is a date rather than a number. Under Art. 218(5) of the Directive, reference medicinal products for which the marketing authorization application was submitted before the date of application remain subject to the data-protection periods of Art. 10 of Directive 2001/83/EC, and Art. 180(4) of the Regulation does the same for centrally authorized reference products, which keep Art. 14(11) of Regulation (EC) No 726/2004. The dividing line is the reference product's application date, not its authorization date and not the date of the biosimilar's own filing. With application set at twenty-four months after entry into force under Art. 219(1) of the revised Directive, and entry into force on the twentieth day after an Official Journal publication that had not occurred as of publication, formal adoption by the European Parliament and the Council being expected in autumn 2026, two populations of reference products will coexist for the better part of a decade. One population sits on the outgoing 8+2(+1) and its biosimilar entry dates were computable. The other sits on 8+1 with conditional years, and its dates are not computable.3 A biosimilar portfolio built across both populations carries two different kinds of uncertainty for what looks like one molecule class, and the sorting variable is a submission date that no register flags as a regime marker. For a centrally authorized reference product it has to be read out of the procedural history in the published assessment report, and for a nationally authorized one out of the public assessment report, product by product.
The reform shortens the guaranteed clock by a year and moves every remaining year into the originator's file. The entrant plans against a horizon fixed by variations it does not see, vouchers it does not hold and a submission date it cannot read.
2. Art. 56a of the Directive: A Door That Opens in One Member State
Art. 56a of the Directive was written as an obligation on originators, and the originator's exposure under it has been analyzed on this site. Read from the other side it is a filing trigger. A Member State may, within one year of the marketing authorization, request the holder of a protected product to place it on its market and supply it so that the needs of its patients are covered, and may attach a pricing-and-reimbursement application, procurement conditions or a roll-out plan to the request under Art. 56a(2) of the revised Directive. Where, within three years of that request, the holder has not, within the limits of its responsibilities, made the product available and supplied it continuously, Art. 56a(5) of the revised Directive provides that the market protection under Art. 80(2) of the revised Directive, and any prolongation of orphan market exclusivity under Art. 72(2) of the Regulation, shall not apply within that Member State. Art. 56a(5a) requires the Member State to make that information public without undue delay and, for centrally authorized products, to notify the Agency. Art. 56a(6) of the revised Directive then does something no earlier text did. By way of derogation from Art. 80(1) of the revised Directive, a generic or biosimilar application may be validated and assessed six years after the start of the reference product's data protection where a Member State has published such information, although the authorization may not be granted before the data protection period expires.6Directive ST-6367/26 (n 2), Art. 56a(1), (2), (4), (5), (5a), (6), (7) and (8), Art. 219(1a); Regulation ST-6366/26 (n 3), Art. 71(2), Art. 72(1) and (2).
The consequence is an exclusivity map drawn at Member State resolution. For a centrally authorized biosimilar the marketing authorization is Union-wide and, under Art. 56a(6) of the revised Directive, may be granted at the expiry of the data protection period, the end of year eight, or of year nine where a voucher year has been added. The bar on placing on the market in Art. 80(2) of the revised Directive continues to apply everywhere except the Member State whose publication lifted it. One authorization and one product can then carry a launch date in Riga or Lisbon and a different one in Berlin. Art. 219(1a) of the revised Directive brings the mechanism forward. A Member State may apply Art. 56a of the revised Directive from twelve months after entry into force to products authorized after entry into force, and for products authorized between entry into force and the date of application the ten-year market bar of Directive 2001/83/EC likewise falls away in the requesting Member State where the holder has not supplied. The first requests under this mechanism, and the three-year supply windows they open, could therefore begin before the Package's own general date of application, even though the launches they permit wait for the reference product's data protection to expire. Whether such requests will be made is a question about originator conduct, Member State appetite, the words "within the limits of its responsibilities" in Art. 56a(5) of the revised Directive and the exceptional-circumstances clause in Art. 56a(8) of the revised Directive. None of those is visible to an entrant deciding in year four whether to build a dossier for a year-six filing. Where the reference product is an orphan biologic the door is narrower still, because the lapse reaches the prolongation of market exclusivity under Art. 72(2) of the Regulation and not the substance-level exclusivity of Art. 71(2) of the Regulation that sits beneath it.
The compromise text saw the diversion problem and answered part of it. Under Art. 166(5) of the revised Directive a wholesale distribution authorization holder, or anyone engaged in sale at a distance, shall not make a generic or biosimilar that benefits from a disapplication under Art. 56a(5) of the revised Directive available on the market of another Member State where the protection still applies, during the period of that protection, and a wholesaler exporting to a Member State where the protection has lapsed must keep specific records for three years.7Directive ST-6367/26 (n 2), Art. 166(5), Art. 85(1) and (3); Regulation (EU) 2019/933 (SPC manufacturing waiver), Art. 5(2) of Regulation (EC) No 469/2009 as amended. That is an obligation on wholesalers and distance sellers. It is not a statement about what the originator may do with a patent or supplementary protection certificate still in force in the launching Member State, and the Package's Bolar expansion in Art. 85 of the revised Directive covers preparatory activity, not placing on the market. So the door Art. 56a(5) of the revised Directive opens is a regulatory one. Whether an entrant can walk through it depends on the patent estate in that one Member State, on whether the six-month stockpiling window of the SPC manufacturing waiver in Regulation (EU) 2019/933 can be aligned with a lapse date the entrant did not choose, and on whether a supply chain built for a Union launch can be confined, in fact and in evidence, to a single national market for the years in which the records under Art. 166(5) of the revised Directive run. A launch that is lawful in one Member State and a diversion breach in twenty-six is a new shape of risk for a product category whose compliance model has been continental.
What the entrant also cannot know is whether the originator will cure. Art. 56a(7) of the revised Directive preserves the holder's right to make the product available through national procedures at any time regardless of a request, and the three-year period under Art. 56a(5) of the revised Directive runs from the Member State's request, a date the entrant sees only when the Member State publishes. A biosimilar dossier validated under Art. 56a(6) of the revised Directive in year six is a bet that a specific originator will still be out of a specific market in year eight. The publication under Art. 56a(5a) of the revised Directive records a state of affairs, not a commitment.6
3. Biosimilar or Bio-Hybrid: Where the Definition Sets the Evidence
The second thing the Package fixes from the entrant's side is the evidence package, and it does so through a definition. Art. 4(14a) of the Directive defines a biosimilar medicinal product as a biological medicinal product that is similar to a reference medicinal product and has the same strength, pharmaceutical form and route of administration. Art. 11 then asks for the results of appropriate comparability tests and studies, with the type and quantity of supplementary data set by Annex II and the detailed guidelines, and provides that the results of other tests and studies from the reference product's dossier shall not be provided. A biological that differs from the reference product in strength, pharmaceutical form, route of administration or therapeutic indications is a bio-hybrid under Art. 12 of the revised Directive, and for it the applicant must supply the non-clinical or clinical results necessary to establish a scientific bridge to the reference data and to demonstrate the product's safety and efficacy profile.8Directive ST-6367/26 (n 2), Art. 4(12), (13) and (14a), Art. 6(2), Art. 11, Art. 12, Art. 84, Annex II. The line matters commercially because differentiation is how a later entrant competes. The choices are a higher-concentration presentation or a subcutaneous route where the reference product is intravenous. Either of those choices moves the product across the boundary drawn by Art. 4(14a) of the revised Directive and out of the pathway of Art. 11 of the revised Directive, and the bridging data that Art. 12 of the revised Directive requires is not defined in the text. It is defined case by case, against a reference product whose own data the entrant may not use. Art. 4(12) of the revised Directive adds a wrinkle of its own. The reference product must be one that is or has been authorized in the Union, so a reference product withdrawn from the Union market remains a reference product, and its data protection continues to run under Art. 80(5) of the revised Directive in Member States where it is no longer authorized.
What the detailed guidelines require is moving, and it is moving in a direction that makes the definitional line more consequential rather than less. In its reflection paper on a tailored clinical approach in biosimilar development, adopted by the CHMP on 16 March 2026 after a draft released for consultation on 27 March 2025 with comments open until 30 September 2025, the Agency states that comparative efficacy studies are no longer expected to be required for the approval of biosimilars that can be thoroughly characterized with state-of-the-art analytical methods and have demonstrated similarity in physicochemical and functional properties, an approach it expects to apply to the majority of biosimilar candidates, with analytical comparability and pharmacokinetic data carrying the demonstration.9EMA, 'Reflection paper on a tailored clinical approach in biosimilar development' (EMA/CHMP/BMWP/60916/2025, CHMP 16 March 2026). A comparability exercise that no longer needs a comparative efficacy trial is a cheaper and faster program, which lowers the cost of the route under Art. 11 of the revised Directive. It does nothing for a bio-hybrid, whose bridge under Art. 12 of the revised Directive is measured against exactly the clinical questions the tailored approach removes for the plain biosimilar. The economics of differentiation therefore shift under the entrant's feet. The undifferentiated product becomes cheaper to build, and the differentiated one does not.
Interchangeability sits in the Package at recital level and nowhere else. Recital 27 records the Member State authorities' joint statement that fifteen years of experience show approved biosimilars to be comparable to their reference product in efficacy, safety and immunogenicity and therefore interchangeable. Recital 136 draws the advertising consequence, that it would be misleading to suggest in advertising that a biosimilar is not interchangeable with its reference product or with another biosimilar of the same reference product. The joint statement itself, issued by the EMA and the Heads of Medicines Agencies in September 2022 and updated in April 2023, says in the same breath that decisions on how to implement interchangeability, whether by switching under the prescriber's control or by substitution at pharmacy level, are outside the Agency's remit and are managed by the individual Member States.10Directive ST-6367/26 (n 2), Recitals 27 and 136; EMA and HMA, 'Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU' (EMA/627319/2022). There is no operative article on substitution in the Directive. For a US developer that is the inverse of the BPCIA architecture. In the United States interchangeability is a product-specific regulatory status under § 262(k)(4), conferred by the FDA and carrying its own first-interchangeable exclusivity under § 262(k)(6), and pharmacy substitution follows from it under state law. In the Union interchangeability is a scientific presumption attached to every approved biosimilar, and substitution is a national policy that can differ twenty-seven ways and change without any change to the product. The FDA's own position is converging on the science. Its draft guidance of 29 October 2025 proposes that a comparative efficacy study may not be necessary where a comparative analytical assessment shows the proposed biosimilar to be highly similar, and its June 2024 draft on interchangeability proposed that switching studies will generally not be needed either.11FDA draft guidance on the need for comparative efficacy studies (29 October 2025); FDA draft guidance on interchangeability (June 2024); BPCIA (n 1), § 262(k)(4) and (k)(6). A developer that reads the two agencies as aligned on evidence may miss that they remain structurally opposite on what the resulting approval is worth at the pharmacy counter.
One provision in the Package runs the other way and is easy to overlook because it sits in a chapter written for originators. Art. 84 of the revised Directive grants a four-year period of data protection for a new therapeutic indication not previously authorized in the Union for the active substance, where adequate studies demonstrate a significant clinical benefit and the product is authorized under Art. 9 to Art. 12 of the revised Directive and has not previously benefited from data protection, or twenty-five years have passed since its initial authorization. The period may be granted once.8 A biosimilar holder that develops a new indication for its own product can therefore hold data protection against other biosimilars for that indication while remaining an entrant against the reference product. Whether that is a strategy or a curiosity depends on the indication landscape of the molecule and on how competent authorities will read "not previously authorised in the Union for the active substance(s)" where the reference product holds the indication somewhere else in the world. No guideline had addressed the point as of publication.
4. Switzerland: A Ten-Year Clock and a Price Gap Keyed to Patents
Switzerland is not a Member State of the European Union, and none of the provisions above apply there. Switzerland publishes its own clock in its own way, since Swissmedic orders and publishes the document protection with the authorization and must publish the duration of every protection granted under Art. 11a and Art. 11b HMG, but the Swiss clock for the same reference product runs on its own statute and on none of the Package's arithmetic. Under Art. 11a of the HMG, the documents supporting a product that contains at least one new active substance are protected for ten years. Art. 11b HMG adds three years for documents supporting a new indication, route of administration, dosage form or dosage, ten years on application for a new indication of expected significant clinical benefit supported by extensive clinical trials, ten years for a product developed exclusively for pediatric use under a pediatric investigation plan, and fifteen years for an important medicinal product for rare diseases. Art. 12(2) HMG then sets the filing window. Absent the holder's written consent, an essentially similar product may be authorized at the earliest on the day after the protection expires, and the application may be submitted at the earliest two years before that.12Heilmittelgesetz (HMG) (SR 812.21), Art. 11a, Art. 11b(1) to (4), Art. 12(1) and (2); Arzneimittelverordnung (VAM) (SR 812.212.21), Art. 30 Abs. 5 and Art. 68 Abs. 1 Bst. d. There is no separate market-protection year. The Swiss architecture is a single ten-year term with a two-year filing window at its end, against the Union's eight plus one plus conditional years, and the two terms start on different days. The Swiss term runs from Swissmedic's authorization, which for a product filed with the Agency first can sit months behind the Union decision. A biosimilar with a single global comparability program therefore faces two expiry dates for one reference product, and which of them falls later depends on whether the originator has earned its conditional years in the Union and on how long Swissmedic's review took a decade earlier.
Swissmedic's guidance on biosimilar authorization, in the version valid from 1 October 2025, applies those terms with a rule the entrant feels before the science does. Where the reference product's document protection still has more than two years to run on the date the application is received, and the holder has not consented, Swissmedic does not enter into the application, a rule that Art. 30 Abs. 6 VAM sets and the guidance restates. The same guidance confirms that a first-authorized biosimilar receives no document protection of its own under Art. 11a HMG, permits the comparability exercise to use, with justification, a reference product authorized by the European Commission or the FDA in place of the Swiss reference product, and expects clinical comparability to be demonstrated in at least one relevant sensitive patient population, in one indication and at one dose, with extrapolation to other indications on justification.13Swissmedic, 'Wegleitung Zulassung Biosimilar' (ZL101_00_012, Version 6.0, 1. Oktober 2025); VAM (SR 812.212.21), Art. 30 Abs. 6. That last expectation is where the Swiss and Union positions moved apart within a single year. The Agency's March 2026 reflection paper removes the routine comparative efficacy study for well-characterized biologics. The Swiss guidance, in the version in force at publication, does not remove it. A program designed to the Agency's tailored approach may arrive in Bern without the study Swissmedic's guidance describes, and whether Swissmedic follows the Agency, on what timetable and for which molecules, had not been settled by any published revision as of publication.
Authorization is the smaller half of Swiss market entry. Reimbursement runs through the Spezialitätenliste, and the ordinances that govern admission to it have treated biosimilars as a class with arithmetic of its own since 1 January 2024. Art. 64a(5) of the KVV defines a biosimilar by reference to a Swissmedic-authorized reference product. Art. 65c bis KVV treats a biosimilar as economical on admission where its ex-factory price sits at least 20, 25, 30 or 35 % below the reference product's, the tier depending on the reference product's average annual Swiss market volume in the three years before patent expiry, with bands at CHF 8, 16 and 25 million, measured on an independent institute's sales surveys, which the BAG may require the biosimilar applicant to report. Art. 65d ter KVV re-tests the gap at each three-yearly review at 10, 15 or 20 % against the reference price then in force.14Verordnung über die Krankenversicherung (KVV) (SR 832.102), Art. 64a(5), Art. 65c bis, Art. 65d ter, Art. 67a(3). Two things about that rule matter to an entrant that has computed its entry date under the HMG. The volume window is measured before patent expiry, not before the expiry of document protection, so an entry that follows the HMG clock is priced against a patent date the entrant has to establish separately. And the discount is set by the originator's historic Swiss volume, a figure the entrant does not hold and must buy.
The demand side moved on the same date. Art. 38a of the KLV raises the insured person's co-payment to 40 % for a product whose ex-factory price exceeds the average of the cheapest third of products with the same active substance by at least 10 %. Since 1 January 2024 that rule applies to biological reference products and their biosimilars as it does to originators and generics, with the cheapest third reset on the listing of the first biosimilar. Art. 38a(6) KLV then gives the originator a defense the entrant should expect. A reference-product holder that cuts its price in one step, after patent expiry, to the Art. 65c bis KVV level keeps the 10 % co-payment for twenty-four months, which removes the co-payment lever from the biosimilar at the moment it launches. Art. 38a(7) and (8) KLV carve out prescriptions that require the reference product for documented medical reasons and oblige prescribers and pharmacists to tell patients when a biosimilar is listed and the co-payment exceeds 10 %.15Krankenpflege-Leistungsverordnung (KLV) (SR 832.112.31), Art. 38a(1), (2), (4), (6), (7) and (8), Art. 38(4) and (5). Art. 52a of the KVG, as amended with effect from the same date and explained in the BAG's circular of 5 December 2023, allows a pharmacist to substitute a listed biosimilar for the reference product unless the prescriber expressly requires the reference product. Art. 38(4) and (5) KLV, in force from 1 July 2024, recalculate the distribution margin on the average ex-factory price of the biosimilars once the first one is listed, so that the margin no longer rewards dispensing the dearer product.16Bundesgesetz über die Krankenversicherung (KVG) (SR 832.10), Art. 52a, in force since 1 January 2024; BAG circular of 5 December 2023. Swiss entry is therefore a system in which the regulator's clock, the patent, the originator's volume history, a co-payment rule and a pharmacist's substitution right all bear on the same launch, and none of them appears in the Union analysis above.
5. Strategic Considerations for Biosimilar Entrants
The questions that decide an entry program are, in this landscape, mostly questions about someone else's file. Which of a portfolio's reference products submitted their marketing authorization applications before the date of application, and so remain on the outgoing arithmetic, is knowable only by reconstruction from each reference product's published assessment report, because no list sorts the two populations. Whether a mid-sized reference product will receive a voucher in its fifth or sixth year is knowable only once the Agency publishes the transfer. Whether an originator has earned its conditional year, and which one, becomes visible when a variation is granted and a national list or the Union Register is updated. An entrant that models a nine-year horizon is modeling the floor, and the ceiling is two years higher on facts it will learn in sequence and late.
Behind those sit questions the text leaves open. One is whether a Member-State-limited launch under Art. 56a(5) of the revised Directive is separable, in practice, from the Union-wide authorization it sits under. Another is how Art. 166(5) of the revised Directive will be enforced against a wholesale chain that spans the launching Member State and its neighbors, and who bears the liability when product crosses that line. A third is whether the exceptional-circumstances clause in Art. 56a(8) of the revised Directive will be read narrowly enough for the door to open at all, and a fourth whether a differentiated presentation is worth the bio-hybrid classification once the tailored clinical approach has made the plain biosimilar cheaper to build. Each of those turns on facts about a specific molecule, a specific originator's conduct in a specific Member State and a specific dossier, and none of them had been tested against a published decision as of publication.
For a US-listed entrant or originator the loop back to US law is direct. The loss-of-exclusivity dates that appear in the risk factors required by Item 105 of Regulation S-K, and the launch guidance given to investors, have on the Union side become conditional statements about events in other companies' files. A date disclosed as fixed that turns out to have been a floor is a disclosure question before it is a regulatory one. And the settlement culture that has governed US biosimilar timing sits under a European competition law that, since the Court of Justice's judgment in Generics (UK), treats a settlement delaying entry as a restriction by object where the value transferred to the entrant has no explanation other than the parties' interest in not competing, so that a global settlement calendar negotiated on BPCIA terms is a document a European authority may read differently.1717 C.F.R. § 229.105 (Regulation S-K, Item 105); Case C-307/18 Generics (UK) v Competition and Markets Authority ECLI:EU:C:2020:52. The Unified Patent Court, whose provisional measures reach a biosimilar launch in every participating Member State at once, adds a forum whose timing the entrant also does not control.
Whether a given program sits on the right side of each of these lines depends on the reference product's regulatory history, the patent and certificate estate in each Member State and in Switzerland, the dossier the entrant has chosen to build and the contracts that connect its supply chain to its launch markets. Those are questions of fact and of drafting, and they require analysis tailored to the molecule, the markets and the commercial context.